Several predictors for the efficacy of lenvatinib (4-week relative dose intensity [19], AFP [20,21], ALBI grade [20,21,22], neutrophil-to-lymphocyte ratio [23], and occurrence of hypothyroidism [24]) have been reported previously. This evidence concerns the gene AFP and hypothyroidism.